As of 2024-12-14, the Relative Valuation of Myriad Genetics Inc (MYGN) is (23.64) USD. This relative valuation is based on P/E multiples. With the latest stock price at 14.50 USD, the upside of Myriad Genetics Inc based on Relative Valuation is -263.0%.
The range of the Relative Valuation is (24.16) - (27.19) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.1x - 21.3x | 17.5x |
| Forward P/E multiples | 19.0x - 21.8x | 19.6x |
| Fair Price | (24.16) - (27.19) | (23.64) |
| Upside | -266.6% - -287.5% | -263.0% |
| Date | P/E |
| 2024-12-12 | -11.38 |
| 2024-12-11 | -11.39 |
| 2024-12-10 | -12.04 |
| 2024-12-09 | -11.68 |
| 2024-12-06 | -11.87 |
| 2024-12-05 | -12.84 |
| 2024-12-04 | -13.03 |
| 2024-12-03 | -12.74 |
| 2024-12-02 | -13.10 |
| 2024-11-29 | -12.77 |
| 2024-11-27 | -12.78 |
| 2024-11-26 | -12.69 |
| 2024-11-25 | -12.33 |
| 2024-11-22 | -12.16 |
| 2024-11-21 | -11.87 |
| 2024-11-20 | -12.01 |
| 2024-11-19 | -11.77 |
| 2024-11-18 | -11.95 |
| 2024-11-15 | -11.97 |
| 2024-11-14 | -12.31 |
| 2024-11-13 | -12.38 |
| 2024-11-12 | -12.69 |
| 2024-11-11 | -13.59 |
| 2024-11-08 | -13.66 |
| 2024-11-07 | -13.87 |
| 2024-11-06 | -13.79 |
| 2024-11-05 | -13.82 |
| 2024-11-04 | -13.99 |
| 2024-11-01 | -14.12 |
| 2024-10-31 | -17.23 |
| 2024-10-30 | -17.87 |
| 2024-10-29 | -17.48 |
| 2024-10-28 | -17.23 |
| 2024-10-25 | -16.92 |
| 2024-10-24 | -17.12 |
| 2024-10-23 | -17.52 |
| 2024-10-22 | -17.75 |
| 2024-10-21 | -17.69 |
| 2024-10-18 | -18.36 |
| 2024-10-17 | -18.31 |
| 2024-10-16 | -18.77 |
| 2024-10-15 | -18.82 |
| 2024-10-14 | -19.70 |
| 2024-10-11 | -18.90 |
| 2024-10-10 | -18.11 |
| 2024-10-09 | -19.13 |
| 2024-10-08 | -20.37 |
| 2024-10-07 | -20.52 |
| 2024-10-04 | -20.77 |
| 2024-10-03 | -20.74 |